New drug trial targets dangerous liver fat
Disease control
Recruiting now
This study is testing an investigational drug called HU6 to see if it is safe and can reduce harmful fat in the liver for people with MASH, a serious form of fatty liver disease. About 180 adults aged 30 and older with MASH will receive either HU6 or a placebo for 26 weeks, and r…
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC